Filing Flows › Agilent Technologies (A) › Q3 FY26 › vs Q2 FY26
Agilent Technologies (A) Q3 FY26 vs Q2 FY26 (quarter over quarter)
Agilent Technologies's revenue rose $43.0M (+2%) from $1.8B in Q2 FY26 to $1.9B in Q3 FY26. The biggest changes: Agilent CrossLab +$27.0M (+4%); Life Sciences and Diagnostics Markets +$14.0M (+2%); Applied Markets +$2.0M (+0.6%). Operating margin 23.6% against 21.7% (+1.9 pts).
Agilent Technologies, Q3 FY26: revenue $1.9B (+8% year over year), operating margin 23.6%, net earnings $362M, operating cash flow $519M. The chart draws each line against Q2 FY26, the increases inside each band.
Margins
| Q3 FY26 | Q2 FY26 | Change | |
|---|---|---|---|
| Operating margin | 23.6% | 21.7% | +1.9 pts |
| Net margin | 19.3% | 18.5% | +0.8 pts |
| Free cash flow margin | 23.4% | 11.0% | +12.4 pts |
Every line
| Line | Q3 FY26 | Q2 FY26 | Change | % |
|---|---|---|---|---|
| Agilent CrossLab | $786M | $759M | $27.0M | +4% |
| Life Sciences and Diagnostics Markets | $746M | $732M | $14.0M | +2% |
| Applied Markets | $346M | $344M | $2.0M | +0.6% |
| Revenue | $1.9B | $1.8B | $43.0M | +2% |
| Operating profit | $444M | $399M | $45.0M | +11% |
| Costs & expenses | $1.4B | $1.4B | −$2.0M | -0.1% |
| Pre-tax earnings | $444M | $408M | $36.0M | +9% |
| Cost of revenue | $836M | $845M | −$9.0M | -1% |
| Research & development | $123M | $126M | −$3.0M | -2% |
| SG&A | $475M | $465M | $10.0M | +2% |
| Net earnings | $362M | $339M | $23.0M | +7% |
| Income tax | $82.0M | $69.0M | $13.0M | +19% |
| Depreciation & amortization | $66.0M | $67.0M | −$1.0M | -1% |
| Share-based compensation | $32.0M | $32.0M | $0 | 0% |
| Working capital & other | $59.0M | −$161M | $220M | — |
| Operating cash flow | $519M | $277M | $242M | +87% |
| Free cash flow (OCF − capex) | $439M | $201M | $238M | +118% |
| Capital expenditures | $80.0M | $76.0M | $4.0M | +5% |
Questions
How much did Agilent Technologies's revenue grow quarter over quarter in Q3 FY26?
Agilent Technologies's revenue rose $43.0M (+2%) from $1.8B in Q2 FY26 to $1.9B in Q3 FY26.
What drove Agilent Technologies's revenue change in Q3 FY26?
Agilent CrossLab +$27.0M (+4%); Life Sciences and Diagnostics Markets +$14.0M (+2%); Applied Markets +$2.0M (+0.6%).